Research Objective

This study assesses whether the viral load in HIV‑infected patients receiving long‑term antiretroviral therapy declines or remains stable. It also examines the emergence of new genetic mutations under drug‑suppressed conditions.

Population and Design

Adults (≥18 years) enrolled in other NIH protocols, who are virologically suppressed on antiretroviral therapy with very low plasma viral levels, will be recruited. Participants will attend the NIH Clinical Center every six months for physical examinations, blood draws, and leukapheresis. Leukapheresis isolates leukocytes from blood for immune‑cell profiling.

Expected Impact

If the virus continues to decline, a therapeutic goal approaching complete suppression may become attainable. Conversely, a stable viral set point would suggest that current regimens have reached their efficacy ceiling, underscoring the need for novel therapeutic strategies. The presence or absence of emergent mutations could serve as a critical biomarker for next‑generation antiretroviral drug development.

Market and Industry Significance

The HIV therapeutic market generates several billion dollars annually, and the identification of new resistance mechanisms could substantially affect both generic and pipeline drug portfolios. Although the research is government‑funded, its outcomes may enable commercialization of biomarker platforms and immune‑cell analysis technologies. Investors should therefore monitor this long‑term therapeutic innovation trajectory.